Because METTL3 plays a critical role in catalytic activity, many studies regarding its biological function in cancers have been widely reported, including lymphoma (29, 30), leukemia (31–33), breast cancer progression (34), liver cancer (35), glioblastoma (36, 37), bladder cancer (38, 39), gastric cancer (40), and lung cancer (41, 42). This evidence concerns the gene METTL3 and leukemia.